Article Text

AB1098 Autoimmune Disease and Cancer: Results from A Retrospective Cohort
  1. S. Pier Paolo1,2,
  2. E. Boggio1,
  3. M. Gentile1,
  4. E. Merlotti1,
  5. D. Sola1,
  6. R. Luca1,
  7. M. Pirisi1,2,
  8. M. Bellan1
  1. 1Immunorheumatology Unit- SCDU Medicina Interna 1, Università degli Studi del Piemonte Orientale “A.Avogadro”
  2. 2IRCAD (Interdisciplinary Research Center of Autoimmune Diseases), Novara, Italy


Background The pathogenetical association between autoimmunity and cancer has been previously described.

Objectives In this study we aimed to better describe the complex relationship between autoimmunity and neoplastic diseases in a retrospective cohort from our outpatient Immunorheumatology clinic. In particular we aimed to identify those immune conditions the diagnosis of which is associated to an increased risk of being diagnosed for a cancer within 2 years before and after the rheumatological syndrome onset.

Methods We evaluated 3975 clinical records from 1st January 2005 to 30th November 2012. We used non immune-mediated conditions (fibromyalgia and osteoarthritis) as controls. We included in the analysis only patients with at least 2 years of follow-up.

Results We reported 144/1750 cases of cancer in the general population (8.2% [6.91 – 9.49]), 41/702 of which (5.9% [4.16–7.64]) in control group. The prevalence of cancer was increased in patients affected by Sjogren's Syndrome (18.3% [8.52–28.08]; OR 3.62 [1.75–7.48]), Dermatomyositis/Polimyositis (42.9% [6.24–79.56]; 12.09 [2.65–55.8]), Vasculitis (18.8% [9.23–28.37]; 3.70 [1.81–7.52]) and Polimyalgia Rheumatica (24.0% [15.63–32.37]; 5.09 [2.92–8.88]). Logistic regression identified all these diagnosis, age >65 and male sex as independent risk factors for neoplastic disease.

Conclusions DM/PM, vasculitis and PMR show an increased risk of neoplasms during the whole observation period and a high prevalence of symptoms remission after cancer treatment as expected for a paraneoplastic manifestation; vice versa Sjogren's Syndrome seems to be more likely a causal factor for cancer (in particular lymphoma), since the risk is increased exclusively in the prospective follow-up and the treatment of cancer is not associated to a remission of rheumatological symptoms.

Disclosure of Interest None declared

DOI 10.1136/annrheumdis-2014-eular.1955

Statistics from

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.